PCDHGC3

Across TCGA pan-cancer cohorts, PCDHGC3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PCDHGC3 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PCDHGC3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHGC3 expression acts as an unfavorable survival marker, although some lineages such as STAD and GBM show a favorable association.

ESCA, STAD, and HNSC are the cancer types where PCDHGC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.187	0.528	.005	15	view →
STAD	DFS	Median	II,III,IV	1.000	0.364	.011	14	view →
HNSC	DFS	Median	II,III,IV	0.194	0.661	.031	9	view →
PRAD	DFS	Median	All	0.617	0.886	.045	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	OS	Median	All	1.000	0.257	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PCDHGC3–ESCA (DFS)

Open the ESCA breakdown →